Aprea Therapeutics, Inc.

APRE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$12,959-$14,287-$112,662-$37,127
Dep. & Amort.$22$7$186$272
Deferred Tax$0$0$0$0
Stock-Based Comp.$489$444$16,981$7,814
Change in WC-$1,055$1,619-$1,759-$8,327
Other Non-Cash-$54$39$72,242-$317
Operating Cash Flow-$13,557-$12,178-$25,011-$37,686
Investing Activities
PP&E Inv.-$15-$93$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$15-$93$0$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$16,140$5,789$683$1,539
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$1,318-$649$0$208
Financing Cash Flow$14,822$5,140$683$1,747
Forex Effect-$7-$8$39-$2
Net Chg. in Cash$1,243-$7,139-$24,289-$35,942
Supplemental Information
Beg. Cash$21,648$28,787$53,076$89,018
End Cash$22,890$21,648$28,787$53,076
Free Cash Flow-$13,572-$12,271-$25,011-$37,686
Aprea Therapeutics, Inc. (APRE) Financial Statements & Key Stats | AlphaPilot